IRVINE, Calif.–(BUSINESS WIRE)–Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today commented on Valeant Pharmaceuticals International, Inc.’s (“Valeant”) release of its second quarter 2014 earnings results. Following Valeant’s earnings conference call on July 31, 2014, Allergan’s financial advisors and forensic accountants analyzed Valeant’s reported financial and operating results, identifying numerous inconsistencies and omissions. Further, Valeant’s 46-page July 31 second quarte

from Business Wire Merger/Acquisition News